Want to see GDTC full AI Analyst Report?
GDTC Stock Chart & Stats
$0.95
-$0.41(-13.85%)
At close: 4:00 PM EST
$0.95
-$0.41(-13.85%)
Day’s Range― - ―
52-Week Range$0.68 - $3.68
Previous CloseN/A
Volume107.31K
Average Volume (3M)18.30K
Market Cap
$10.41M
Enterprise Value$11.79M
Total Cash (Recent Filing)$1.46M
Total Debt (Recent Filing)$453.76K
Price to Earnings (P/E)―
Beta0.03
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,832,835
10 Day Avg. Volume26,787
30 Day Avg. Volume18,295
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)3.07
Price to Sales (P/S)62.86
P/FCF Ratio-4.56
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue16.37
Enterprise Value/Gross Profit-19.87
Enterprise Value/Ebitda-2.01
Forecast
1Y Price Target
$4.16Price Target Upside337.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe sharp increase in TTM revenue indicates meaningful commercial expansion and growing activity in the business. If the company can retain this trajectory while controlling costs, a larger revenue base could eventually support operating leverage and improve the economics of its development programs.
Modest LeverageLow debt relative to equity reduces immediate balance-sheet pressure and limits the burden of interest obligations while the company develops its pipeline. This gives management more flexibility to direct available resources toward operations and may reduce near-term solvency risk.
Loss ReductionThe narrower interim loss, supported by other operating income and tighter cost controls, suggests some progress in managing the expense base. Although the company remains unprofitable, sustained discipline could gradually reduce funding needs and improve its path toward financial stability.
Bears Say
Persistent Cash BurnPersistent negative operating and free cash flow means the business is consuming cash rather than funding itself internally. Unless burn moderates, continued reliance on external capital may constrain strategic flexibility, increase financing requirements, and make pipeline investment harder to sustain.
Severe UnprofitabilityNegative gross profit and substantial operating losses show that revenue growth has not yet translated into an economically viable model. Continued losses limit internal reinvestment capacity and indicate that stronger sales alone may not produce durable earnings without improved cost structure and margins.
Balance-Sheet ErosionDeclining equity and assets alongside persistently negative returns indicate that ongoing losses are weakening the company’s financial base. If this pattern continues, additional capital could be needed to fund development, creating value-dilution risk and reducing long-term financial resilience.
CytoMed Therapeutics Limited News
GDTC FAQ
What was CytoMed Therapeutics Limited’s price range in the past 12 months?
CytoMed Therapeutics Limited lowest stock price was $0.68 and its highest was $3.68 in the past 12 months.
What is CytoMed Therapeutics Limited’s market cap?
CytoMed Therapeutics Limited’s market cap is $10.41M.
When is CytoMed Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CytoMed Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is CytoMed Therapeutics Limited overvalued?
According to Wall Street analysts CytoMed Therapeutics Limited’s price is currently Undervalued.
Does CytoMed Therapeutics Limited pay dividends?
CytoMed Therapeutics Limited does not currently pay dividends.
What is CytoMed Therapeutics Limited’s EPS estimate?
CytoMed Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CytoMed Therapeutics Limited have?
CytoMed Therapeutics Limited has 11,832,835 shares outstanding.
What happened to CytoMed Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CytoMed Therapeutics Limited?
Currently, no hedge funds are holding shares in GDTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CytoMed Therapeutics Limited
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
GDTC Stock 12 Month Forecast
Average Price Target
$4.16
▲(337.89% Upside)
Technical Analysis
Ownership Overview
34.84% Insiders
0.04% Mutual Funds
0.19% Other Institutional Investors
64.93% Public Companies and
Individual Investors